Stefan Holdenrieder
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Geiger K, Jörger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy. Tumour Biol 2024; 46:S355-S367.
Jan 1, 2024Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Jan 1, 2024Tumour Biol 2024; 46:S355-S367
Geiger Kimberly, Jörger Markus, Roessler Max, Hettwer Karina, Ritter Christoph, Simon Kirsten, Uhlig Steffen, Holdenrieder Stefan
Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K, Jörger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy. Tumour Biol 2024; 46:S191-S206.
Jan 1, 2024Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Jan 1, 2024Tumour Biol 2024; 46:S191-S206
Geiger Kimberly, Jörger Markus, Roessler Max, Hettwer Karina, Ritter Christoph, Simon Kirsten, Uhlig Steffen, Holdenrieder Stefan
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nassar Y, Ojara F, Pérez-Pitarch A, Geiger K, Huisinga W, Hartung N, Michelet R, Holdenrieder S, Jörger M, Kloft C. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework. Cancers (Basel) 2023; 15
Nov 15, 2023C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nov 15, 2023Cancers (Basel) 2023; 15
Nassar Yomna M, Ojara Francis Williams, Pérez-Pitarch Alejandro, Geiger Kimberly, Huisinga Wilhelm, Hartung Niklas, Michelet Robin, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Jörger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725.
Feb 27, 2023A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Feb 27, 2023CPT Pharmacometrics Syst Pharmacol 2023; 12:1714-1725
Ojara Francis Williams, Henrich Andrea, Frances Nicolas, Nassar Yomna M, Huisinga Wilhelm, Hartung Niklas, Geiger Kimberly, Holdenrieder Stefan, Jörger Markus, Kloft Charlotte
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel) 2021; 13
Dec 14, 2021Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Dec 14, 2021Cancers (Basel) 2021; 13
Mc Laughlin Anna M, Schmulenson Eduard, Teplytska Olga, Zimmermann Sebastian, Opitz Patrick, Groenland Stefanie L, Huitema Alwin D R, Steeghs Neeltje, Müller Lothar, Fuxius Stefan, Illerhaus Gerald, Jörger Markus, Mayer Frank, Fuhr Uwe, Holdenrieder Stefan, Hempel Georg, Scherf-Clavel Oliver, Jaehde Ulrich, Kloft Charlotte, For The On-Target Study Consortium